• Skin metastasis of TNBC is typically local.
• Metastatic TNBC is typically histologically high grade.
• CK5/6, p40 and p63 expression can be seen in metastatic TNBC to the skin, but is usually focal. However, rarely, CK5/6 can demonstrate strong diffuse expression, correlating to basal phenotype.
• p40 and p63 were more specific than CK5/6, with metastatic TNBC demonstrating no to focal expression of p40 and p63.
• CK5/6, p40 and p63 remains a useful panel in differentiating metastatic breast carcinoma from CAN, even with TNBC.
cBioportal as a Tool to Monitor and Analyze Next
Generation Emory University Hospital, Design: Totally 168 melanoma samples from 07/27/15 to 07/24/17 were tested in Emory Molecular Diagnostic Laboratory for next generation sequencing (NGS) based mutation profiling with Illumina TruSight® Tumor 26 gene panel. The cases were de-identified and the presumably significant variants reported by pathologists were uploaded to a local cBioportal platform. The anatomic site and tumor percentage were included. We compared the variant profiles in our local database with TCGA database of variants from cutaneous melanoma provisional cohort (471 samples). The results were used for monthly quality review and molecular tumor board presentation.
Results: BRAF, NRAS and TP53 are the three most commonly mutated genes found in our melanoma cases. MUC16 is the most commonly mutated gene in TCGA dataset; however, it is not tested in our targeted panel (Fig. 1, MUC16 not included). The prevalence of NRAS and TP53 variants are comparable between our data and TCGA dataset; BRAF mutations are more common in TCGA cohort. The types of genetic alterations detected in our cases are also similar to TCGA cohort (Fig. 2) . All the variants we reported, were detected in TCGA dataset. The main source of differences can be attributed to the different number of genes targeted, because TCGA data was collected from whole exome sequencing.
Conclusions: In our study, we noticed that our melanoma cases match well with those from TCGA provisional cohort. cBioportal is a useful platform for quality control and quality assurance. The web browser interface also makes it a convenient tool for our monthly molecular tumor board to present the cumulative data to the clinical oncology team. Background: Kaposi sarcoma (KS) is an HHV-8 infection related vasoproliferative disorder that may arise in different clinical backgrounds including immunocompetent and immunocompromised patients (classic and endemic vs. AIDS-related and iatrogenic). KS lesions in immunocompromised patients may regress after restoration of the immune system by antiretroviral therapy or withdrawal of the immunosuppressive agents. In this study we sought to evaluate a possible interaction between Programmed Death-1 (PD-1) receptor on T-cells and its potential ligands on KS cells that may play a role in which tumor cells evade immunity in immunocompetent patients.
Design: PDL-1 expression was assessed by immunohistochemistry using VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody on a series of 42 KS lesions from 31 patients of different clinical backgrounds, summarized in table. Early patch stage lesions were not included in the study. Three pathologists blinded to the clinical background performed the evaluation of PDL-1 expression. A 1% cutoff value was used for positive staining in tumor cells. PDL-1 expression was scored by multiplying staining intensity by percentage of positive tumors cells (H-score). The mean of H-scores in positive samples was calculated for each patients group.
Results: PDL-1 was more frequently expressed with higher mean H-score in iatrogenic KS due to autoimmune diseases (6/7; 85%/ mean score=24) and immunocompetent patients (11/14; 78%/ mean score=21) in contrast to transplanted patients (3/9; 33%/ mean score=6). PDL-1 expression in AIDS related KS was present in (7/12; 58%/ mean score=10). None of the lesions in any patients group showed strong and diffuse staining. PDL-1 expression in all patients groups was present in (27/42; 64%) with overall mean H-score for positive samples=15. Conclusions: PDL-1 expression in KS is seen in 64% of cases, which tends to be focal and weak to moderate at most. PDL-1 is expressed more frequently in iatrogenic KS due to autoimmune diseases (85%) and immunocompetent patients (78%) in contrast to transplanted patients (33%). PDL-1 expression in AIDS related KS is seen in 58% of cases. The variable expressions of PDL-1 among different patient groups may represent a minor adaptive mechanism of tumors cells to evade the immune response. To the best of our knowledge, this is the first study evaluating PDL-1 expression in KS of different clinical backgrounds. Additional studies may be needed to explore the role of PDL-1 in Kaposi sarcoma. The University of Texas MD Anderson Cancer Center, Houston, TX Background: Presence of multiple BAP1-negative melanocytic neoplasms is a hallmark of familial cancer susceptibility syndrome caused by germline mutations in BAP1. The syndrome is characterized by increased incidence of renal cell carcinoma, mesothelioma, cholangiocarcinoma, cutaneous and uveal melanoma and other neoplasms, including basal cell carcinoma. Melanocytic tumors lacking BAP1 expression may also present as sporadic lesions in patients lacking a germline mutation.
Melanoma with Loss of Bap1 Expression in
Design: Here, we report histomorphologic and clinical characteristics of cutaneous melanomas with loss of BAP1 expression in 4 patients with no known history of BAP1-associated cancer susceptibility syndrome (Figure 1) .
Results:
The tumors were nodular melanomas characterized by predominantly intradermal proliferation of large epithelioid (spitzoid) melanocytes with nuclear pseudoinclusions as well as scattered multinucleated cells, arising in association with a standard intradermal nevus. Of all 4 patients, only 1 had multiple recurrences with in-transit and regional lymph node metastases. FOR TABLE DATA, SEE PAGE 215, FIG. 452 Conclusions: To the best of our knowledge, this is the first series of cutaneous melanomas with loss of BAP1 expression arising in a sporadic setting. 
NCI, NIH
Background: Keratoacanthomas (KAs) are fast-growing, benign, ephemeral tumors that occur on sun-exposed skin and resemble well differentiated cutaneous squamous cell carcinoma (SCC).
Transforming growth factor-beta (TGF-beta) inhibits cell cycle progression, and reduced TGF-beta signaling has been implicated in KA formation. Patients with Ferguson-Smith disease develop KA-like multiple self-healing squamous epitheliomas due to loss-of-function germline mutations in the TGF-beta receptor gene. Here we report four cases of treatment-emergent KAs developing in cancer patients receiving a novel bifunctional protein that fuses a human monoclonal antibody against programmed death ligand 1 (PD-L1) to the soluble extracellular domain of TGF-beta receptor II. This drug functionally traps and neutralizes TGF-beta.
Design:
The clinical courses of four cases of treatment-related KAs were reviewed. Lesions were biopsied and confirmed by histopathological examination.
Results: Four patients (mean ages: 60.5; arrange: 50-73), including 3 females and 1 males, with diagnosed solid malignancies received infusions of the novel bifunctional protein every two weeks as part of a Phase I clinical trial. Three patients developed multiple KA-like lesions on sun-exposed areas within 2-3 moth treatment, and one patient had one solitary, crateriform nodule on his chin within one month treatment. Representative lesions from each patient were biopsied and confirmed to be KAs or well differentiated SCC, KAtype by histopathological examination. Lesions on two patients were documented to partially spontaneously regress by serial clinical evaluations over the course of weeks while continuing treatment.
Conclusions:
Together with the genetic defect in patients with Ferguson-Smith disease, these cases confirm the pathophysiological importance of reduced TGF-beta signaling in KA formation. Further investigations are needed to identify the predisposing molecular and genetic changes required for KA formation as well as to define the natural history of these treatment-associated skin tumors. The University of Texas MD Anderson Cancer Center, Houston, TX Background: Spiradenoma and cylindroma are related tumors, with morphological overlap and hybrid tumors encountered. These are described as sweat gland tumors and considered to be of eccrine lineage. The associations with trichoepitheliomas/ Brooke-Spiegler, combinations with hair follicle tumors, and anatomical considerations are proposing a folliculosebaceous-apocrine lineage. A subset of dermal cylindromas shows the MYB-NFIB gene fusion/ MYB protein overexpression, similar to adenoid cystic carcinoma. Quantifying the differential expression of genes in various human organs/tissues/ cell types is vital to understand physiology/disease. Several studies analyzed expression of protein-coding genes across tissues.
A Magnifying Glass on Spiradenoma and Cylindroma Histogenesis-Systematic Transcriptome Analysis
Design: 22 cutaneous neoplasms formed the material of this study. 14 of these along with 7 normal skin were microdisected from FFPE. RNA pools were subjected to expression profiling using whole-transcriptome shotgun sequencing; differentially expressed candidates were analyzed by IHC.
Results: The tumors were classified as 11 spiradenomas, 4 cylindromas, 3 hybrids (spiradenomas/cylindromas), 1 chondroid syringoma, 2 adnexal carcinomas, 1 BCC. Age at diagnosis 25-92 yo, female predominance (n=14), more frequent in head and neck (n=13: scalp-7, ear-4, face-2). Differential gene expression profiles from 7 spiradenomas, 2 cylindromas, 3 hybrids, 2 adnexal carcinomas versus 7 normal skins were generated and compared to each other. 4004 genes and noncoding transcripts were detected as differentially expressed at 0.01 FDR. These genes and transcripts were annotated and analyzed using the IPA program. Highest expressed genes were predominantly developmental-related genes (ODAM,DMRTA2,HOXB13,TLX1,SOX14, BARX1,HOTAIR,HOXC11) along with lincRNAs. For RNA-Seq results validation, IHC assessed protein expression of 4 genes highly upregulated and considered important for spiradenomas/ cylindromas. These candidates were ODAM, HOXB13, MYB and SOX10 with expressions at 69%, 74%, 79% and 81% respectively.
Conclusions:
We assume that spiradenomas and cylindromas are mainly defined by high number of overexpressed developmental/ homeobox genes, which provide the potential for transformation/ plasticity, along with differentiation and proliferation behavior of neoplastic cells. These data form the basis for understanding cell fate determination and cellular homeostasis in the normal adnexal epithelium and the contribution of different adnexal cell types to the etiology/ molecular pathology of dermal adnexal disease. Background: It still remains largely unknown how melanocytes transform into melanoma cells. However, there is enough evidence documenting the link between intense UVR exposure and melanoma, characterized with an elevated number of C>T (by UVB) or G>C (by UVA) conversions in the DNA of melanomas arising in sun-exposed skin (lentigo maligna-type melanoma).
Mature microRNAs (miRNAs) are small (~22 nucleotides) endogenous RNAs that may regulate gene expression such as by post-transcriptional induction of mRNA decay or by repressing mRNA translation into proteins. It is estimated that miRNAs are able to modulate up to 60% of protein-coding genes in the human genome and are centrally involved in the control of proliferation, differentiation, apoptosis, and other important biological pathways. miRNAs may be aberrantly expressed or mutated in cancer and can function as potential oncomiRs (miRNAs with either oncogenic or tumor-suppressing functions), by targeting the transcripts of the genes involved in carcinogenesis. miRNA expression profiles can also be employed for classification of human cancers according to the development lineage and differentiation state.
Questions: 1) Do superficial (UV-damaged) and deep melanocytes of nevi in sun-exposed skin differ in their miRNA expression? 2) Are some of those differentially expressed miRNAs known potential oncomiRs?
Design: Superficial and deep melanocytes were LCM microdissected from nevi of 15 patients. The suspensions were processed for hybridization to a ribonucleotide protection system with 2280 total probes including 2256 micro RNA probes targeting 2083 human micro RNAs.
Results: A comprehensive analysis of all human miRNAs registered in miRBase 11.0 was performed using the HTG Molecular Diagnostic database. A hierarchical cluster analysis of the miRNAs (FDR<0.1) was performed to visualize the miRNA species upon which the samples can be best classified as superficial or deep melanocytes. This yielded statistical relevant miRNA profiles with FDR<0.1 for 14 samples.
We identified 39 miRNAs that were differentially expressed between the superficial and deep melanocytes. Ingenuity pathway analysis (IPA) suggested the gene transcripts AR, MDM2, Smad2/3, YBX1 as most probable miRNA targets, with ongoing validation at the protein level.
Conclusions: Superficial (UV-damaged) melanocytes can be differentiated from deep melanocytes on the basis of the expression of 39 miRNAs, with AR, MDM2, Smad2/3, YBX1 as candidates for the gene transcript and protein targets. 
University of Michigan
Background: Melanocytic lesions with borderline features are diagnostically challenging. Molecular techniques based on detection of genomic copy number alterations (CNA) using single nucleotide polymorphism (SNP) arrays can be helpful in predicting whether a lesion is likely to behave in an indolent or aggressive manner (i.e. like a nevus or a melanoma). Fluorescence in situ hybridization (FISH) has been used as a quicker, less expensive alternative to SNP array, employing a panel of probes that may be gained (RREB1, MYC, CCND1), or lost (MYB, homozygous CDKN2A loss) in melanoma. While the sensitivity and specificity of FISH testing are both reported to be in excess of 90%, validation studies are based on well-characterized nevi and melanoma rather than borderline melanocytic tumors.
Design: We used SNP array data from 63 borderline cutaneous melanocytic lesions and 45 definitive melanomas, which served as a control group, to predict the performance of FISH testing. Lesions were considered positive by "virtual FISH" if one or more of the 5 FISH-probed loci demonstrated appropriate CNAs by SNP array. Cases were classified as positive by SNP array if 3 or more CNA (>3 MB each) were present, or if the FISH criteria were met. Additionally, lesions which had only gains or losses of entire chromosomes were designated as negative, regardless of changes at the FISH loci, as this pattern is characteristic of benign proliferative nodules. Conventional FISH was performed in 31 cases.
Results: Of the 63 borderline cases, 44 (70%) were positive by SNP array and 29 (46%) were positive by virtual FISH. A higher proportion of melanomas were positive by SNP array (42/45, 93%) and virtual FISH (36/45, 80%). Compared to SNP array, virtual FISH failed to recognize 19 cases with concerning CNAs (false negatives, Fig. 1A ) and incorrectly classified as positive 3 cases with whole chromosome gains and losses (false positives, Fig. 1B) . Sensitivity of virtual FISH compared to SNP array was 86% in the melanoma group but only 57% in the borderline group, while specificity was 100% and 84% in these groups, respectively. There was good correlation between conventional and virtual FISH, with agreement in 18/19 conventional FISH positive and 11/12 negative cases.
Conclusions: While FISH is highly effective in distinguishing between nevi and melanoma in cases where the histological diagnosis is straightforward, it is not nearly as sensitive or specific as SNP array when applied to borderline melanocytic lesions. Background: Glomus tumors (GT) arise from modified smooth muscle of the normal neuromyoarterial glomus body that regulates temperature and pressure, usually benign and subungual in females. We previously defined malignant GT as >2 cm, subfacial/visceral, with nuclear atypia, atypical or increased mitoses, and often with a benign peripheral rim and wanted to review our recent institutional experience.
Design: Slides, blocks, clinical, phenotypic and molecular data of cases coded as "GT" from 2007-2017 were pulled and analyzed, excluding glomus jugulare and other tumors.
Results: 27 subungual (5M;21F, mean age 46 years, mean size 0.6 cm) and 28 extradigital (20M: 8F, mean age 56 years, mean size 2.0 cm) GT were identified in local, obese patients, with BMI mean 33 and 31, respectively. Subungual GT patients had cold intolerance, nail dystrophy, and pain worse at night, involving 8 thumb, 7 ring, 4 5th, 4 index, and 1 each of 3 rd toe, 3 rd and unknown finger, of equal sides. Extradigital GT patients had friable, bleeding, blue masses that caused regional paresthesia, involving 15 forearm, 6 leg, 3 thigh/buttock, and 1 each neck, flank, stomach, and palm. Both types had a feeder vessel with surrounding nerve twigs and scattered mast cells. Extradigital GT exhibited greater internal staghorn vascularity and even cavernous with thrombus, whereas subungual had fewer staghorn. Most GT were located in reticular dermis and abutted subcutis (suprafascial equivalent), composed of epithelioid cells without classic distinctive cytoplasmic borders.
One subungual and 10 extradigital had "atypical" features of blue rim with central pink larger cells, at least moderate nuclear atypia, and a multifocal infiltrative pattern; one locally recurred. Extradigital with larger size, deep, spindling, binucleation, increased mitotic activity, or rare necrosis met criteria for uncertain (n=2) or malignant (n=2), without known recurrences or metastases over 6 years follow-up.
Conclusions: Most GT occur at normal glomus body depth and do not exhibit distinctive cytoplasmic borders. Feeder vessel neurovasoconstriction, possibly influenced by mast cell histamine, may cause pain in subungual and paresthesia in extradigital. Extradigital appears to be as common as subungual GT, with a striking male predilection, older age, larger size, and higher propensity for deep, atypical and malignant. The relationships of higher regional BMI to clinical symptoms and our genetic and phenotypic data to outcome are yet to be determined. Background: Granular cell tumors (GrCT) of granular nerve sheath phenotype exhibit distinctive cytoplasmic lysosomal inclusions. We previously described histologic criteria for atypical and malignant GrCT. After an index malignant case, we wanted to review our recent institutional experience with GrCT.
Design: Slides, blocks, phenotype, and reports on cases coded as "GrCT" from our institutional files, 2007-2017, were pulled and analyzed. Cases re-classified as congenital granular cell epulis or other were excluded. Histologic criteria used for atypical and malignant were as we previously described, additionally requiring increased or atypical mitoses and/or necrosis for malignant. Targeted molecular phenotypic data and multivariate analysis are pending.
Results: 44 GrCT occurred in 33 patients: 22 females, 11 males, mean age 36, age range 4-70, years, and mean tumor size 1.7 cm. The largest sizes, 4.6, 6.0, and 15.5 cm, ultimately correlated with histologically malignant.
GrCT were equal sided and originally involved aerodigestive mucosa of esophagus (n=5), cecum/colon (n=5), and one each stomach, trachea, endobronchial, or skin/soft tissue of arm/finger (n=5), thigh/leg/foot (n=5), chest/breast (n=4), head and neck (n=3), vulva (n=2) and penis (n=1). 8 patients, one each leg, arm, head and neck, penis, trachea, endobronchial, and two esophageal, underwent 1-3 reexcisions at the same site over 1 to 7 years. Lesions without atypia were considered multifocal synchronous and metachronous, with persistent disease, including penis, both esophageal, and endobronchial.
Most granular cell tumors were infiltrative in dermis/subcutis equivalent, with recurrent and ultimately atypical or malignant tumors involving deep muscle. Tumors classified as atypical (n=6, recurrent = 2) or ultimately malignant (n=3, recurrent = 2, metastatic = 1) demonstrated looser Zellballen pattern, in addition to other required histologic criteria.
Conclusions:
GrCT, most common in skin/soft tissue sites in middle aged females, exhibit loss of cohesive Zellballen pattern as another atypical feature. Multiple GrCT are multifocal rather than multicentric and involve skin/soft tissue-only or visceral-only, synchronous or metachronous, including histologically-benign usually upper aerodigestive tract "persistent" disease. Our designation as "atypical" or "malignant" correlates with size, depth and behavior. Studies to compare genetic/phenotypic analysis with classification and outcome are underway. Design: Paraffin-embedded formalin-fixed tissues from 10 MACs were studied by targeted, multiplexed PCR-based DNA nextgeneration sequencing (NGS) of the coding sequence of over 400 cancer-relevant genes.
Genetic Profiling of Microcystic Adnexal Carcinoma
Results: Somatic mutation burden was variable, with an average of 10 prioritized nonsynonymous mutations per tumor (range: 2-30). Based upon prioritized mutations, the majority of tumors lacked UV signature mutational profiles. Mutations in either NOTCH2 or NOTCH4 were present in 3 tumors. EGFR mutations were detected in 2 tumors, including 1 mutation previously identified in lung carcinoma. TP53 mutations were not detected. Multiple copy number alterations were detected in 9 tumors. Recurrent alterations included gains of MAF or MAFB (40%), gains of CEBPA (40%), losses of TCF3 (40%), and losses of PAX7 (40%). Arm-level gains were identified in 4 tumors, 2 of which displayed gains of 8q suggesting a role for MYC. Considering both amplifications and mutations, mutually exclusive alterations in EGFR or FGFR family tyrosine kinases were present in 4 tumors. None of the genetic changes were significantly associated with clinical or histopathologic features.
Conclusions: To our knowledge, this is the first NGS study of MACs. Our cases demonstrate heterogeneous genetic changes including both somatic mutations and copy number alterations, with potential drivers involved in dysregulated receptor tyrosine kinase signaling and MAF transcription factor activation. Despite classically arising on sun-damaged skin, MAC differs from more common skin tumors such as squamous cell carcinoma and basal cell carcinoma, in that MAC is less consistently associated with UV signature mutations and lacks TP53 mutations. Our findings suggest that there may be multiple molecular subtypes of MAC, and their distinct genetic changes may have potential diagnostic and therapeutic implications. 
Maastricht
Background: Merkel cell carcinoma (MCC) is a highly aggressive non-melanoma skin cancer of the elderly which is associated with the Merkel cell polyomavirus (MCPyV). MCC reveals a trilinear differentiation characterized by neuroendocrine, epithelial and pre/pro B-cell lymphocytic marker expression. However, the cellular origin of MCC remains elusive.
Design: Here we investigated the expression of the neuroendocrine key regulators Re-1 silencing transcription factor (REST), neurogenic differentiation 1 (NeuroD1) and the Achaete-scute homologe 1 (ASCL1) in MCC.
Results: The expression of REST in MCC was analysed by immunohistochemistry (IHC) in 28 formalin fixed and paraffin embedded MCC tissues. Further, MCPyV-positive (MKL-1, MKL-2 and WaGa) and MCPyV-negative (MCC13 and MCC26) MCC cell lines and the B-ALL cell-line REH as positive control were tested for REST, ASCL1 and NeuroD1 expression. Quantitive and normal RT-PCR was used to confirm the results of the cell lines on the transcriptional level. Q-RT-PCR was used to illustrate the expression of neuroendocrine genes: chromogranin A, synaptophysin and miRNA miR-9 and miR-9* in the cell lines.
REST tagged with GFP was inserted into WaGa cells and analyzed for their expression of chromogranin A and synaptophysin. In addition, the regulation of the REST expression by methylation was assessed with the demethylating agent 5-aza-2'-deoxycytidin. Further the methylation status of the CpG islands of the REST promoter was analysed with a methyl specific PCR (MSP).
We found that all MCCs are devoid of REST and ASCL1 and express NeuroD1. Further, the REST expression is restricted to MCPyVnegative MCC cell lines. NeuroD1 was detected in all cells and tissues. The lack of the neuroendocrine master regulator ASCL1 in almost all tested MCCs points to an important role of the absence of the negative regulator REST towards the MCC neuroendocrine phenotype. This is underlined by the expression of the REST-regulated microRNAs miR-9/9* in REST-negative MCC cell lines. Background: The fibrohistiocytic tumors of the skin constitute a heterogeneous group of mesenchymal neoplasms whose diagnosis can be particularly challanging, especially in superficial biopsies. The assessment of an appropriate immunohistochemical panel is crucial to guide pathologists in the diagnosis and classification of these tumors.
Design: The aim of the study was to evaluate the immunohistochemical expression of Galectin-3 and Cathepsin K in a cohort of cutaneous fibrohistiocytic and undifferentiated lesions (25 dermatofibromas, 3 atypical dermatofibromas, 3 dermatofibrosarcoma protuberans, 4 undifferentiated pleomorphic sarcomas). A group of several other lesions (3 Kaposi sarcomas, 3 neurofibromas, 1 cutaneous leiomyoma, 1 piloleiomyoma,) were also taken into account as reference. Each case was semiquantitavely scored by the proportion of positive cells and staining intensity.
Results: Strong and diffuse immunoreactivity for Galectin-3 and Cathepsin K was found in all dermatofibromas (25/25, 100%) and atypical dermatofibromas (3/3, 100%), and in all undifferentiated pleomorphic sarcomas (4/4, 100%). Cases of dermatofibrosarcoma protuberans have shown a patchy and weak background staining, in contrast to the diffuse, strong and crisp staining seen in fibrohistiocytic tumors. None of the other lesions were immunolabeled by the two markers.
Conclusions: Galectin-3 resulted to be a novel and sensitive marker in cutaneous fibrohistiocytic and undifferentiated lesions. Interestingly, the combined expression of Galectin-3 and Cathepsin K was found to be constantly and strongly observed in dermatofibroma, including its variants, and in cutaneous undifferentiated pleomorphic sarcoma. Our findings suggest that Galectin-3 and Cathepsin K can be used as a part of the immunohistochemical panel for the diagnosis of fibrohistiocytic and undifferentiated lesions, and they result to be particularly helpful in superficial biopsies when facing problematic and ambiguous cases. Brigham and Women's Hospital, Boston, MA Background: Epithelioid fibrous histiocytoma is a rare and distinctive cutaneous neoplasm. Most cases harbor ALK rearrangement and show ALK overexpression, which distinguish this neoplasm from conventional cutaneous fibrous histiocytoma and variants. SQSTM1 and VCL have previously been shown to partner with ALK in one case each of epithelioid fibrous histiocytoma. The purpose of this study was to examine a large cohort of epithelioid fibrous histiocytomas by next-generation sequencing to characterize the nature and prevalence of ALK fusion partners.
PREVIOUSLY PUBLISHED
Design: A retrospective archival review was performed to identify cases of epithelioid fibrous histiocytoma received from 2012 -2016. Each case was re-reviewed to confirm the diagnosis, and immunohistochemistry was performed to confirm the presence and pattern of ALK expression. Targeted next-generation sequencing was applied on RNA extracted from formalin-fixed paraffin-embedded tissue to identify the fusion partners. The results were analyzed using both Manta and JAFFA fusion callers.
Results: Twenty-three cases fulfilled inclusion criteria and contained RNA suitable for analysis. The mean patient age was 39 years (range, 8 -74 years), there was no sex predilection, and >75% of cases involved the lower extremities. The most common gene fusions were SQSTM1-ALK (N=12; 52%) and VCL-ALK (N=7; 30%); the other four cases harbored novel fusion partners (DCTN1, ETV6, PPFIBP1, and SPECC1L). The pattern of ALK immunoreactivity was usually granular cytoplasmic staining (N=12; 52%) or granular cytoplasmic and nuclear (N=10; 43%); the case containing an ETV6 fusion partner showed nuclear staining alone. There was no apparent relationship between tumor morphology and the ALK fusion partner.
Conclusions: SQSTM1 and VCL are the most common ALK fusion partners in epithelioid fibrous histiocytoma; DCTN1, ETV6, PPFIBP1, and SPECC1L represent rare fusion partners. The proteins encoded by these genes play diverse roles in scaffolding, cell adhesion, and transcription (among others) without clear commonalities. These findings expand the oncogenic promiscuity of many of these ALK fusion genes, which drive neoplasia in tumors of diverse lineages with widely varied clinical behavior. This is the first documented account of ETV6-ALK and SPECC1L-ALK translocations in neoplasms. Background: Mycosis fungoides (MF) is an indolent cutaneous T-Cell lymphoma. Recent studies show that tumor microenvironment (TM) plays a crucial role and may determine disease progression and tumor escape from immunosurveillance. T cells are exposed to persistent inflammatory signals that lead to "T cell exhaustion", which manifests with progressive loss of effector functions and sustained upregulation of multiple inhibitory receptors, including programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3).
Tumor Microenvironment in Mycosis Fungoides
Our aims are to evaluate the expression of PD1, its ligand PDL1 and LAG3 in a cohort of patients (pts) with MF and to evaluate whether it may have an impact on overall survival (OS).
Design: 65 patients (36males, 29 females, median age: 55yo) with MF were reviewed, with a mean follow-up of 125 months (range: 6-450m). 52 pts were diagnosed as early stage (I&IIa) and 13 pts as advanced stage (>IIb). Large cell transformation was observed in 12 pts. All cases were stained with PD1 (clone NAT105), PDL1 (clone 22C3) and LAG3 (clone 11E3). Statistical analysis was performed.
Results: MF cells expressed PD1 in 92% of cases, in early stages with a low proportion (<20%) of PD1-positive cells, while in advanced stages most cases expressed PD1 in more than 20% of neoplastic cells (p=0.001) ( Table 1) . PDL1 was expressed in more than 5% of cells in 15 cases, mainly in the cytoplasm of macrophages, but not in neoplastic cells (Table 1) . LAG3 was positive in few lymphocytes in only 2 cases. We found no correlation between PD1, PDL1 and LAG3 expression. Cytological atypia, age >60yo and advanced stage had a negative impact on OS (p<0.05). A weak correlation between atypia, PD1-positive cells and PD1 intensity was found (r<0.5).
PD1 < 20%
PD1 >20% PDL1 <5% PDL1>5%
Early stage 37 15 40 12
Advanced stage 3 10 10 3
Conclusions: In our series, most cases expressed PD1 indicating that TM may play a role in MF. We also found PDL1 expression in TM of our cases, suggesting that PD1/PDL1 pathway could be implicated in tumor escape from immunosurveillance, as seen in different solid tumors. However, we couldn't demonstrate a statistical correlation between PD1, PDL1 and LAG3, raising the possibility that others PD1-ligands, such as PDL2, have a role in MF. Moreover, the high expression of PD1 in MF indicates that it could be useful as an additional therapeutic target in MF. University of Calgary and Calgary Lab Services, Calgary, AB Background: Currently, no universal protocol exists for the assessment of sentinel lymph nodes (SLNs) in cutaneous melanoma. Many institutions employ a multi-step approach with multiple hematoxylin and eosin (H&E) and immunohistochemical stains. However, this can be a costly and time-, and resource-consuming task. Our objective is to assess the utility for multi-step protocols in the analysis of melanoma SLNs by specifically evaluating the SLN protocol at our institution (which consists of 3 H&Es, one S-100 protein, one HMB-45, and one Melan-A slide per melanoma SLN block) and to develop a more streamlined protocol.
Design: Histological slides from SLN resections from 195 patients with diagnosed cutaneous melanoma were submitted to our dermatopathology group. Tissue blocks were processed according to our institutional SLN protocol. The slides were rereviewed to determine whether or not metastatic melanoma was identified microscopically at each step of the protocol. Using SPSS software, a decision tree was then created to determine which step most accurately reflected the true diagnosis.
Results: We found with Melan-A immunostain, 99.4% of negative SLNs are correctly diagnosed as negative and 100% of positive nodes are correctly diagnosed as positive. With the addition of an H&E level, 100% of SLNs are accurately diagnosed.
Conclusions:
We recommend routine melanoma SLN evaluation protocols be limited to two steps: one routine H&E stain and one Melan-A stain. This protocol is both time-and cost-efficient and yields high diagnostic accuracy. final diagnoses. The most frequent misdiagnosis was sarcomatoid squamous cell carcinoma (15/25, 60%), followed by spindle cell/ desmoplastic melanoma (4/10, 40%), cutaneous sarcomas and mesenchymal tumors of intermediate malignancy (28/131, 21%) and nodular fasciitis (4/28, 14%). Findings by misdiagnosis are summarized in Table 1 whereas the breakdown by diagnosis of cutaneous sarcomas and mesenchymal tumors of intermediate malignancy is summarized in Table 2 . 
Consultation Patterns in Cutaneous Sarcomas
Benign diag- nosed sarcoma --------------- -------------- -------------- 4/28 (14%) Sarcoma diag- nosed benign 20/131 (15%) -------------- -------------- ------------- Mesenchymal diagnosed non-mesen- chymal 8/131 (6%) ------------- -------------- 0/28 (0%) Non-mesenchy- mal diagnosed mesenchymal --------------- 15/25 (60%) 4/10 (40%) -------------
University of Florida
Background: Studies of heritable changes in human neoplasms traditionally focus on identification of single nucleotide changes that may have diagnostic, prognostic, and/or predictive clinical ramifications. Such approaches can cause delay in discovery as methodology relies on cancer gene panels, requiring a priori knowledge about putative target genes. Moreover, recurrent mutations in many cancers often mark only a portion of all incident cases, due to underlying heterogeneity and variable chromosomal abnormalities that are hallmarks of all cancers.
Design: Herein, we performed a meta-analysis of the melanoma transcriptome available from the Human Protein Atlas database. Specifically, we analyzed 163 genes associated with unfavorable prognosis in a cohort of 102 cutaneous malignant melanoma cases. To start, we manually procured, annotated, and cataloged previous reports on all identified genes using PubMed Central archive to determine whether they have been previously implicated in melanoma tumorigenesis. We then performed two-part gene regulatory network analysis to identify biological pathways implicated in aggressive melanomas. Combined use of these two resources allowed us to identify active genetic pathways in aggressive melanomas.
Results: Examination of 163 genes associated with unfavorable prognosis in malignant melanomas revealed that majority-specifically 114 genes-has not previously been identified as playing a role in melanomagenesis. Additional 34 genes have only rarely been identified as playing a role in melanoma tumorigenesis, with reports limited to a single or a couple of preclinical studies per gene. Remaining 15 genes have been well-studied, with an average of 26 published reports linking each gene to melanoma tumorigenesis. When we compared understudied genes category (less than three published report per gene; n = 148) to well-studied genes (26 published report per gene on average; n = 15), the difference is statistically significant (p = 4.9 x 10 -10 , two-tailed test). Finally, our gene pathway analysis showed that genes associated with unfavorable prognosis in malignant melanomas belong to DNA replication and cell cycle pathways.
Conclusions: Combining publically-available raw datasets and bioinformatics platforms provides an attractive alternative for pathology-based research. Our study highlights that most genetic factors governing melanoma tumorigenesis are understudied and that more work is needed to elucidate the genetic basis of melanoma growth. Background: Superficial / cutaneous malignant peripheral nerve sheath tumor (cMPNST) is a rare, soft tissue neoplasm that shares an immune molecular signature and morphological features with spindle and desmoplastic melanoma (S/DM). Herein we seek to investigate a possible DNA methylome signature based on differentially methylated regions (DMR) for diagnostic and prognostic purposes.
Design: DNA from formalin-fixed, paraffin-embedded (FFPE) tissue was extracted and processed. Methylation status was assessed using Infinium Methylation EPIC array targeting >850,000 methylation site (CpG) islands. Data from raw files were normalized and analyzed in order to detect differentially methylated regions for coding genes and miRNA (using ANOVA test with adjusted FDR's) with subsequent enrichment and pathway analysis.
Results: Thirty patients (S/DM=15, cMPNST=15, male n=22, female n=8) were included. ANOVA test adjusting for cofounders including age, sex and location, identified 12,209 cancer associated differentially methylated regions (cDMRs) in coding genes and miRNAs (figure 1). Hypo-methylated loci regulating key genes relevant to MPNST were also seen in c-MPNST such as EZH2 (but not BRD4). Some hyper-methylated loci relevant to melanoma were identified in the SDM including mir124 and mir125b. Mir-205 was selectively hypomethylated in the SDM group. 47 hypo-methylated loci regulating zinc finger ZNF family genes involved in transcriptional regulation were identified (27 and 20 hypo methylated loci in cMPNST and SDM, respectively). Loci regulating ZNF473 were hypo methylated in both cMPNST and SDM. 50 long non-coding RNA (lncRNA) loci regulating key genes such as DDITL4 (part of mTOR signaling pathway) were hypermethylated in the SDM group. KEGG Pathway analysis showed the cDMRs to be enriched for BCAT1/c (related Valine, Leucine and isoleucine biosynthesis) in cMPNST but not SDM, adj. p< 0.05. GO pathways analysis showed hypomethylation was increased in multiple pathways related to cell migration, including focal adhesion, cell adhesion, transendothelial migration and extracellular matrix interactions in c-MPNST but not SDM Conclusions: Methylation profile in c-MPNST and SDM differ from MPNST and conventional melanoma . ZNF473 upregulation is involved in cMPNST and SDM tumorigenesis. BCAT1/c is a novel and potentially targetable (BCAT1/c inhibitors) methylome signature differentiating cMPNST from SDM. Integration of methylation data with gene expression data is warranted and is underway. Design: Studied were 14 cases of EFH, all ALK immunopositive. The cases were assessed histopathologically as well as for ALK and TFE-3 rearrangements using FISH and ALK gene fusions using next generation sequencing.
SLAM Family
Results: There were 8 female and 6 male patients, ranging in age from 18 to 79 years. All presented with a solitary lesion on the trunk, lower extremities and face, varying from 5 mm to 20 mm. Microscopically, the lesions were mostly polypoid, with or without an epidermal collaret. Two cases exhibited a non-polypoid architecture with an intradermal proliferation of the neoplastic cells. The cells were usually arranged in well-demarcated sheets, rarely with a focal nested/whirling pattern, fascicular areas and perivascular cuffs. The predominant cell type were mononucleated medium-sized to large epithelioid cells with ample eosinophilic to amphophilic cytoplasm. Additionally, a variable number of bi-, tri-or multinucleated, spindled, multilobated, cells with eccentric nuclei, cells with nuclear pseudoinclusions, mucinous and grooved cells were admixed. In 5 cases, the predominant epithelioid cell component consisted of rather small cells, whereas spindled cells dominated in 3 cases. Of these, 2 lesions were composed rather of pale eosinophilic to clear cells, occasioning a resemblance to PEComa or leiomyoma. Immunohistochemically, 11 were positive for TFE-3. The break apart test for ALK was positive in 11 analyzable cases. ALK genes fusions were found in all 11 analyzable cases included SQSTM1-ALK (3), VCL-ALK (3), TMP3-ALK (2), PRKAR2A-ALK (1), MLPH-ALK (1), and EML4-ALK (1). TFE-3 rearrangements/fusions were not found. Background: Three previous studies identified a subset of spitzoid melanocytic lesions carrying ALK fusions, including conventional Spitz nevus, atypical Spitz tumor (AST) and spitzoid melanoma. Few of these nevi and AST were studied by FISH for chromosomal copy number changes and found no features associated with melanoma. Another study investigated 7 lesions for mutations in TERT promoter (TERT-p), with negative results. We present a series of 16 ALK-fused spitzoid neoplasms, describing novel ALK fusions, results of FISH for copy number changes and TERT-p mutations.
Conclusions
Design: All included spitzoid lesions were ALK positive on immunohistochemistry. FISH for ALK break apart probe as well as two sets of FISH targeting 6p25, 11q13, 6p/CEP6, 6q/CEP6, 9p21 and cep9 were performed. ALK gene fusions were studied by next generations sequencing, whereas TERT-p mutations by Sanger sequencing.
Results: There were 10 female and 6 male patients aged 5-40 years. All presented with a solitary lesion, mostly on the extremities. Histopathologically, most lesions were polypoid or dome shaped with a plexiform predominantly dermally located proliferation of fusiform to spindled melanocytes usually with mild to moderate pleomorphism. Due to atypical features (mitoses > 2 per mm2, mitoses at base, heavy inflammation, perineural invasion, marked pleomorphism), 11 cases were classified as AST. The remaining 5 cases represented Spitz -124C>T) . In all patients, the lesions were surgically removed; re-excision was conducted in 2 cases. Follow-up was available for 13 patients, none of whom showed evidence of disease. Follow-up ranged from 4 to 202 months (mean 47.6 mos). In none of the patients was a sentinel lymph node biopsy performed. Background: The diagnosis of malignant melanoma, especially the spindle cell variant, can be challenging because it resembles morphologically other spindle cell tumors and it often lacks immunohistochemical staining with conventional melanoma markers. To date, there is limited information available about the diagnostic utility of expression of PD-1 and PDL-1 in tumors in the differential diagnosis of spindle cell melanoma. The goal of this study is to determine whether the expression of PD-1 and PDL-1 is a useful diagnostic aid.
Design: We identified a cohort of well characterized spindle cell melanoma and its mimickers (different types of benign and malignant peripheral nerve sheath tumors) and retrieved49 cases (13 spindle cell melanomas, 13 MPNSTs, 11 Schwannomas, and 12 neurofibromas). We examined the histological slides, and performed immunohistochemistry for PD-1 and PDL-1 on the block with the greatest amount of well-preserved viable tumor. The percentage of PDL-1 tumor cell staining was scored and PD-1 staining in the tumor and immune cells was assessed. A statistical analysis evaluating the significance of staining patterns was performed to determine whether or not PD-1 and PDL-1 staining has diagnostic utility.
Results: PDL-1 staining of at least 1% of the tumor cells was seen in 9/13(69.2%) spindle cell melanoma, 6/13 (46.2%) MPNST, 0/11 Schwannoma, and 0/12 neurofibroma. More than 5% of PDL-1 staining was seen in 8/13 (61.5%) spindle cell melanoma and 4/13 (30.8%) MPNST. Tumor cell epression of PD-1 was identified in all the cases of PDL-1 staining. One Schwannoma and one neurofibroma showed PD-1 positivity without PDL-1 staining. PDL-1 staining was heterogeneous in the tumor with moderate intensity and cytoplasmic and membranous patterns. PD-1 expression was observed in tumor infiltrating lymphocytes and peritumoral lymphocytes. The percentage of PDL-1 positive tumor cells is higher in spindle cell melanoma than in MPNST, however the result is not statistically significant. PDL-1 expression in malignant tumors (spindle cell melanoma and MPNST) helps to exclude Schwannoma and neurofibroma with statistical significance (p<0.05).
Conclusions: Both spindle cell melanoma and MPNST show expression of PD-1/PDL-1 and staining for these antigens is not helpful in this differential diagnosis. However benign peripheral nerve sheath tumors do not express PDL-1, therefore, a positive result is evidence against these possibilities and this finding can be of diagnostic importance. Background: Hormonal changes in pregnancy have been known to alter melanocytic lesions. Histopathologically, some nevi observed within the context of pregnancy have shown increased mitotic figures with corresponding Ki-67. Additionally, cytomorphologic changes have also been noted, referred to as superficial micronodules of pregnancy. Such changes may alarm the pathologist for malignancy, particularly nevoid melanoma. Immunohistochemistry for p16 have been utilized to distinguish benign nevi from melanoma. We propose the use of p16 immunohistochemistry as utility for characterizing melanocytic nevi from pregnant patients to confirm its benignity.
Design: Formalin Fixed Paraffin-Embedded tissue blocks were obtained for nevi from pregnant patients and also for nevoid melanomas. 14 nevomelanocytic lesions were obtained from 12
Results: For nevi from pregnant patients (n=14), results of p16 nuclear immunohistochemistry were as follows: <5% (1 case, 7%), 5-25% (7 cases, 50%), 25-50% (3 cases, 21.5%), >50% (3 cases, 21.5%). For nevoid melanomas (n=12), results were as follows: <5% (8 cases, 67%), 5-25% (3 cases, 25%), 25-50% (1 case, 8%), >50% (0 case, 0%). Additionally, three nevi from pregnant patients had superficial micronodules of pregnancy with increased dermal mitosis (2-3 mitotic figures/mm 2 within hotspots). Analysis of p16 IHC within the areas of hotspot mitosis did not show any significant difference in p16 staining pattern.
Conclusions:
Results from the current study of nevi from pregnant patients show majority of cases (13 of 14 cases, 93%) with positive p16 nuclear staining that was greater than 5%. In contrast, majority of nevoid melanoma cases (8 of 12 cases, 67%) showed virtually complete loss of p16 nuclear staining or less than 5% of p16 nuclear staining. Its application as a potential immunohistochemistry diagnostic marker to confirm benignity of nevi from pregnant patients may become a useful tool in comparison to nevoid melanomas. Background: Currently, NGS techniques are being widely used as a tool in a routine oncology workflows. Majority of labs use either DNA based panels or two separate DNA and RNA panel to investigate cancer specimens. Any NGS assay choice in a CLIA setting requires careful consideration of the content of the panel, the inclusion of evidencebased markers, and it's compatibility with low quality and quantity of nucleic acids. The objective of our project was to evaluate the utility of a comprehensive 170 genes enrichment-based targeted panel that simultaneously analyzes DNA and RNA in Melanoma. The panel targets all coding exons in 170 genes, 55 genes for fusions and splice variants, 151 SNVs and indels, and 59 amplifications. Assessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
Design: Under an approved IRB protocol (n= 8) Melanoma cases were identified. All these cases were positive for one of molecular abnormalities routinely tested for Melanoma (variants in, BRAF, NRAS, PDGFRA, KIT etc). H&E slides were examined and the diagnoses were confirmed. Subsequently, sequencing was performed on DNA/RNA isolated from FFPE tissue on a NGS platform (NextSeq, Illumina). The variant and fusion calls were read and interpreted on the software provided by the manufacture (Illu Results: All the calls with high confidence on the NGS platform matched 100% with the PCR findings on all the 8 cases Background: Sebaceoma is a benign sebaceous neoplasm that manifests histologically as a well-circumscribed tumor which composed mostly of immature, small, basophilic sebocytes with a variable admixture of mature sebocytes and sebaceous ducts. Some sebaceomas and rare sebaceous carcinomas have been shown to manifest organoid growth patterns, including rippled, labyrinthine/ sinusoidal, carcinoid-like and petaloid. The objectives of this study were to validate this proposition by studying a large number of cases, determine if there are specific associations with clinical features including age, sex and location and determine if they have any association with Muir-Torre syndrome.
Design: The authors have studied 56 sebaceous neoplasms (53 sebaceomas, 3 sebaceous carcinomas) with organoid growth patterns. For each case, particular patterns (rippled, labyrinthine/ sinusoidal, carcinoid-like and petaloid), alone or in combination were documented, and the dominant pattern was also recorded. In 22 cases with available tissue blocks, immunohistochemistry with MMR protein was performed.
Results: The neoplasms occurred in 35 males and 18 females (gender unknown in 3), with ages at diagnosis ranging from 22 to 89 years. Of the 56 tumors, 23 manifested a single growth pattern, 23 had a combination of 2 patterns and 10 a combination of 3 patterns, indicating that these patterns are part of a morphological continuum of changes. The carcinoid-like pattern was the most frequent in the "monopatterned" neoplasms (13 cases), whereas the labyrinthine/ sinusoidal pattern comprised most of the "polypatterned" lesions, in which various combinations occurred. Immunohistochemically, MMR deficiency was detected in 3 of the 22 cases studied, whilst 5 of the 33 patients with available follow-up had an internal malignancy; this however is not indicative of a significant association of these lesions with Muir-Torre syndrome. 
MMR : mismatch repair
Conclusions: Sebaceous neoplasms with organoid growth patterns are predominantly sebaceomas having a predilection for the scalp. In most cases, more than one of the organoid patterns are present. Mature sebocytes may be inconspicuous in these lesions, requiring distinction from other cutaneous adnexal neoplasms. However, these patterns per se may serve as a clue to sebaceous differentiation. These lesions do not appear to be associated with internal malignancy or MMR deficiency in the majority of cases. However, confirmation of the absence of any significant association with MTS will require genetic studies. Bioptical Laboratory SVO, Pilsen, Czech Republic Background: Adenoid cystic carcinoma (ACC) of the skin is a rare, low-grade malignant adnexal neoplasm histologically identical to homonymous tumors in other organs. Approximately 60% of the studied cases of cutaneous ACC have been found to harbor MYB gene activations, either through MYB chromosomal abnormalities or by generation of the MYB-NFIB fusion. In addition to the MYB gene, alterations in MYBL1, the gene closely related to MYB, have been reported in salivary gland ACC. Since we are not aware of any studies on cutaneous ACC studying alterations in MYBL1, our main goal was to find out whether this gene is involved in cutaneous ACC.
A Subset of Adenoid Cystic Carcinoma of The Skin is Associated With Alterations of The MYBL1 Gene Similar to Their Extracutaneous Counterparts
Design: Ten cases of cutaneous ACC with available blocks were randomly selected. In all cases the MYB-NFIB fusions were detected by FISH using one commercial probe, ZytoLight® SPEC MYB Dual Color Break Apart Probe, as well as two own designed SureFish probes, NFIB Break Apart probe and MYB-NFIB Fusion. The break of MYBL1 gene was detected using an own designed SureFish MYBL1 Break Apart probe.
Results: There were 6 females and 4 males, with ages at diagnosis ranging from 51 to 83 years. Locations included the head (n= 4), thigh (n= 2), back (n= 2), and vulva (n=2). All patients presented with a solitary neoplasm, varying is size from 5 to 50 mm in largest dimension (mean 18.6 mm). Histologically, in all but one case, there was a mixture of cribriform, tubular and solid patterns forming variably shaped nodules in the dermis. In the remaining case, solid areas were lacking. In all cases, both true small bilayered ducts and pseudocysts were recognized. Perineural invasion was seen in 4 cases.
MYB-NFIB fusions were found in 4 cases. Remarkably, in 2 of these cases the MYB break-apart probe was negative. The break of MYBL1 was found in in 2 cases. In one of them, the NFIB break apart probe was positive, strongly indicating a MYBL1-NFIB fusion, whereas in the second case, the fusion partner remained unknown. In two cases, the MYB break apart test was positive, whereas no MYB-NFIB was detected, strongly suggesting another fusion partner. In one case, all 4 FISH tests were negative and the remaining case was not analyzable.
FOR TABLE DATA, SEE PAGE 215, FIG. 554
Conclusions: In addition to MYB alterations, some cutaneous ACC exhibit involvement of MYBL1 similar to their extracutaneous counterparts. 
Dartmouth-Hitchcock Medical Center
Background: Endocrine Mucin-Producing Sweat Gland Carcinoma (EMPSGC) is a rare low-grade adnexal malignancy with predilection for the eyelids of older adults. It can recur months to years following incomplete excision although there are no reported metastases. EMPSGC is challenging to distinguish from metastatic breast carcinoma given their overlapping immunophenotypes, and it is easily misdiagnosed in partial biopsies as the requisite neuroendocrine expression and mucin production can be subtle or focal. INSM1 is a new marker that has shown promising sensitivity and specificity in the diagnosis of extracutaneous neuroendocrine carcinomas.
Design: A retrospective search of pathology archives (between 1/2003 and 07/2017) yielded 10 cases of EMPGS. Slides and medical records were reviewed. P63, calponin, synaptophysin, chromogranin, GATA3, ER, PR and INSM1 immunostains were performed on all samples.
Results: Five women and 5 men with median age 78 years (range 56-86) had papules on the eyelid (7 cases) and cheek (3 cases). Clinical work-up excluded the possibilities of metastatic breast carcinoma. 6 received wide excision and 4 Mohs surgery. 2 patients who underwent Mohs and wide excision had local recurrences at 17 and 41 months respectively. 6 had no recurrence over 75 months median duration and 2 were lost to follow-up. 2 lesions had infiltrative architecture and no intact myoepithelial layer (one of them recurred). 2 arose from the linings of hidrocystomas with intact myoepithelial layers (one recurred). The rest showed conventional solid, cystic, and papillary architecture. All had at least focal mucin production. A myoepithelial layer suggesting a probable in situ component was partially intact in 7 cases. 100% of EMPSGC were INSM1 positive (strong nuclear staining in 50%-75% of tumor cells in most cases), 83% stained with synaptophysin, and 67% with chromogranin. All cases were GATA3, ER and PR positive.
Conclusions: INSM1 may have greater sensitivity than synaptophysin and chromogranin for demonstrating neuroendocrine differentiation in EMPSGC. GATA3, ER, and PR are not useful for distinguishing EMPSGC from metastatic breast carcinoma; however, identification of an in situ component supports the diagnosis of EMPSGC. Our cases demonstrated indolent behavior independent of whether the lesions appeared predominantly infiltrative or in situ. Mohs surgery may be a valuable alternative to traditional wide excision in treatment of this disease. Design: Cases of calciphylaxis (n=24), peripheral artery disease (gangrene and uninvolved skin at amputation margin, n=21 each), chronic stasis (n=22), and thrombotic vasculopathy (n=19) were retrospectively reviewed. VK stain was performed and examined in all cases.
Clinicopathologic Features and Calcium
Results: Clinical and histopathologic findings are summarized in the Table. Patients with calciphylaxis were much more likely to be on hemodialysis (p<0.0001) and have documented hypercalcemia, hyperphosphatemia, and/or hyperparathyroidism (p<0.0001). Concentric calcification of subcutaneous small vessels appreciable on H&E is relatively specific for calciphylaxis, although sensitivity was limited (50%). VK allowed for detection of stippled calcium deposits otherwise not appreciable on H&E, but the specificity of such deposits was low. In fact, stippled calcium deposits in subcutaneous small vessels were more common in clinically normal skin (amputation margin) of patients with severe peripheral artery disease (86%) than in calciphylaxis (46%). Specificity of stippled calcium in subcutaneous small vessels (identified on VK only) improved when concomitant thrombosis was present. Calcium deposits in medium-sized vessels, eccrine gland basement membranes, and elastic fibers had minimal specificity.
Calciphylaxis (n=24*) 12 ( Background: Primary anorectal melanoma (AM) is an uncommon melanoma subtype. Although often staged according to the AJCC staging system for cutaneous melanoma (CM) there is limited evidence base to support this practice in AM. Therefore, we analyzed a retrospective cohort of AM patients (pts) to determine if additional or other primary tumor features correlate with DSS.
Design: We identified pts with AM diagnosed and treated at our center and collected clinical (age at diagnosis, sex, ethnicity, anatomic site) and primary tumor pathologic features (tumor thickness, level of rectal wall invasion, vertical growth phase, mitotic rate, ulceration, regression, lymphovascular invasion, perineural invasion, satellitosis, cytology and final resection margin status); and stage at presentation: (L) disease localized to anorectum with (LpN-) or without (LcN-) pathologic lymph node sampling; (R) regional metastases that were clinically occult (RpN+) or clinically evident (RcN+); and (D) distant metastases (Fig 1) . Kaplan Meier methods estimated DSS (Fig 1) .
Univariate and multivariate Cox proportional hazards regression models determined associations with DSS.
Results: 160 AM pts were identified. Median survival was 1.75 years from diagnosis; 1, 5 and 10 year DSS rates were 77%, 22% and 15%; and 121 pts (76%) died due to disease. Within the full cohort, multiple clinical and pathologic features independently associated with DSS, including stage at presentation (Fig 2) . However, when considering distinct subgroups of patients according to stage at presentation, a subset of distinct parameters independently associated with DSS (Fig 2) .
Conclusions: AM is a highly aggressive melanoma subtype with frequent metastasis and death. Similar to CM, increasing tumor thickness associated with reduced DSS in our cohort of AM pts with localized disease or regional metastases. In contrast, primary tumor ulceration was not robustly prognostic of DSS in our cohort of AM pts. Our findings underscore the importance of integrating clinical stage at presentation when determining associations between primary tumor parameters and DSS. Also, our findings strongly support the rationale for additional studies designed to further refine staging and prognostic assessment in AM pts.
Loss of Mismatch Repair Protein Expression Predicts Better Survival In Melanoma
Saleh Najjar Background: Mismatch repair (MMR) proteins including MLH1, MSH2, MSH6, and PMS2 are integral components of the DNA mismatch repair system. Loss of MMR expression is a hallmark of microsatellite instability (MSI). MSI has been reported in 2-30% of primary melanomas and 20-77% of metastatic melanomas. In this study, we aim to evaluate MMR protein expression in malignant melanocytic proliferations and its correlation with survival and other histopathologic parameters.
Design: Formalin-fixed, paraffin-embedded sections from 100 malignant melanocytic proliferations were retrieved from our institution archive. The cohort consisted of 54 primary melanoma, 24 metastatic melanoma, 17 melanoma in situ, 4 mucosal melanoma, and 1 ocular melanoma. The sections were immunostained by automated methods with mouse monoclonal antibodies to MSH2, MLH1, MSH6, and rabbit monoclonal PMS2. MMR protein expression was determined by the percentage of tumor cells with nuclear positivity (PTNP). In addition, the nuclear intensity was scored as absent (0), weak (1), moderate (2), or intense (3). Expression was correlated with histologic variables and survival.
Results: A total of 100 samples were collected from 91 patients (ages 22-90 years, median 64 years, M:F= 1.17:1). The mean MLH1 PTNP was 75.3% ± 17.8, MSH2 67.8% ± 21.8, MSH6 48.2% ± 29.9 and PMS2 65.3% ± 23.9. Loss of 70% or more of any MMR protein expression with weak or absent nuclear intensity score (PTNP< 31% and nuclear intensity score 0 or 1) was associated with 58% reduction in the risk of death (Hazard ratio= 0.42, p = 0.036, Conf. Interval 0.1879-0.9456) and with lower AJCC T category (Tis, T1 or T2) (Pearson chi2 =6.83, p=0.009). Loss of 70% expression or more of any MRR protein regardless of nuclear intensity score (PTNP< 31%) was associated with lower AJCC T category (-0.31, p=0.026) and Clark level (-0.33, p=0.015 Lagos University Teaching Hospital, Nigeria, Lagos Background: Malignant melanoma (MM) is the most lethal of all skin cancers, accounting for about 79% of skin cancer related deaths. In blacks, it is associated with greater morbidity and mortality compared to Caucasians. Studies have shown that MM with BRAF V600E mutation and those with loss of p16 protein expression are associated with aggressive behavior and worse prognosis. BRAF kinase inhibitors have also been approved for treatment of BRAF V600E mutant cases while p16 expression is being proposed as a prognostic marker for MM. No previous study however has been carried out in Nigeria and West African (WA) to determine these facts.
Design: The aim of the study was to determine the BRAF V600E mutation and loss of p16 expression in MM cases in Lagos, Nigeria within the last 10 years and to correlate these with prognostic markers.
Formalin-fixed paraffin-embedded (FFPE) tissue blocks and corresponding archival routine H&E stained slides of all confirmed cases of MM from January 2005 to December 2014 in Anatomic and Molecular Pathology Department of Lagos University Teaching Hospital (LUTH) were retrieved. Cutaneous MM cases were classified into histologic variants. Clark's stage, Breslow thickness and ulceration statuses were determined. Fresh sections from the FFPE tissue blocks were taken for Immunohistochemical (IHC) studies to determine mutant BRAF V600E and p16 protein expression using the VE1 and anti-CDKN2A/p16INK4a monoclonal antibodies respectively.
Results: During the study period 52 MM cases were histologically diagnosed in LUTH which represented 1.0% of total solid malignancies; 43 of these occurred in the skin accounting for 19.7% of all skin cancers and making MM the 3 rd commonest skin cancer after SCC and Kaposi sarcoma. IHC was carried out on 45 cases with viable tissue blocks: 37 cutaneous MM, 3 musosal MM, 2 ocular MM and 3 lymph node metastases. 11% of the cases had BRAF V600E for mutation while 69% had loss of p16 expression.
Conclusions: MM cases in a Nigerian/WA setting are the wild type (BRAF wt) and as such BRAF kinase inhibitors may only be effective in treating very few of our patients. However, the CDKN2A gene pathway is mutated in majority of our cases. Hence, loss of p16 protein expression and delayed presentation may be responsible for the huge and aggressive MM seen in our environment. Approximately 50% of AITL patients have cutaneous manifestations, including maculopapular rash and erythematous eruption, often mimicking inflammatory dermatoses. Moreover, unlike the well characterized pathological features of nodal AITL, the pathological features of cutaneous AITL have not been fully established. Therefore, it is sometimes challenging to differentiate AITL from inflammatory conditions in cutaneous biopsies.
Design: We evaluated the clinical, histological, and immunophenotypic features of 30 cutaneous biopsy samples from 17 AITL patients. Immunohistochemistry for CD2 (n=8), CD3 (n=26), CD4 (n=22), CD5 (n=13), CD7 (n=20), CD8 (n=18), TCR βF1 (n=15), TCR γδ (n=14), CD10 (n=18), BCL6 (n=17), PD1/CD279 (n=23), and CXCL13 (n=12) was performed. Epstein-Barr virus (EBV) was detected using in situ hybridization (ISH) for EBER (n=15).
Results: Samples were obtained from the trunk (n=10), upper extremity (n=9), or lower extremity (n=11). Perivascular infiltration of small-to medium-sized lymphocytes with or without periadnexal distribution was seen in 23/30 (77%) samples; the density of the infiltrating lymphocytes varied considerably. Infiltrates with nodular, interface, and diffuse distributions were identified in 5 (17%), 1 (3%), and 1 (3%) samples, respectively. Granulomas were identified in 3/30 (10%) samples. Infiltrating lymphocytes were generally positive for pan-T cell markers including CD2, CD3, and CD5, while aberrant diminished or absent expression of CD7 was found in 8/30 (27%) samples. The CD4/CD8 ratio was >1 in 13/18 (72%) samples. PD1 was most the frequently expressed T FH marker (22/23 [96%] samples), while CD10, BCL6, and CXCL13 were positive in 10/18 (56%), 15/17 (88%), and 9/12 (75%) samples, respectively. EBV-positive B-cells were detected in 3/15 (20%) samples with varying density. Design: MCLs with cutaneous involvement from our institution were retrospectively reviewed with diagnosis confirmed by expert review.
Results: Twelve specimens from nine patients met the criteria. Patients ranged from 60-87 years (median, 70 years), including 6 males and 3 females. Sites of involvement included head & neck (n=3), trunk (n=5) and extremities (n=4). Of the nine cases, 3 showed classic morphology, 2 were blastoid, 3 pleomorphic and 1 showed marginal zone lymphoma (MZL)-like areas juxtaposed to classic MCL. Four cases presented with cutaneous lesions as the first tissue manifestation of the disease. A second malignancy was identified in 3/9 cases (2 melanoma and 1 papillary thyroid carcinoma). One case showed MCL associated with metastatic melanoma in the same biopsy specimen. By immunohistochemistry, the cells were CD20+ (9/9), CD5+ (8/9), CD23-(9/9), CD10-(7/7), CD43+ (5/6), CyclinD1+ (9/9) and Ki-67 ranged from 60-95%. Peripheral blood flow cytometry was available in 7 cases and was consistent with MCL. FISH was performed on two cases and demonstrated the characteristic t(11,14) translocation. Immunofluorescence studies were done on one case (clinically resembling vasculitis) and showed IgM positivity within the tumor cells. Follow up, available on six cases (mean 32.5 months, range 4-77), showed that 6/6 had Stage IV disease; one patient was alive with disease (4 months follow-up) and the remaining 5 died of disease.
Conclusions: Six out of nine cases in our series demonstrated blastoid, pleomorphic or MZL-like morphologies that could potentially mimic other primary cutaneous lymphomas or leukemia cutis. Rare cases of MCL may show surface IgM expression on immunofluorescence or may occur in association with other malignancies such as metastatic melanoma. Immunohistochemistry for cyclin D1 and FISH for t(11, 14) is helpful for diagnosis. Imaging studies may be necessary to detect systemic involvement in MCL with cutaneous presentation as the first manifestation of the disease as seen in 4/9 cases in our series. 
Design: A retrospective review of whole-exome sequencing results was performed to identify melanomas with NF1 mutations. Twentythree cases with nonsense NF1 mutations that usually result in truncated, non-functional proteins were identified and evaluated for histopathologic features and molecular alterations using 45 melanomas without NF1 mutations as controls. Chi-square or Fisher exact test were used to calculate p-values as appropriate using GraphPad Prism software.
Results: The cohort of NF1 mutated melanomas included primary / locally recurrent (n=11) and metastatic tumors (n=12), from 14 males and 9 females, aged 47-98 years (median, 78 years). Primary sites included head & neck (n=8), extremities (n=7), trunk (n=5), unknown (n=2) and ovary (melanoma arising in mature cystic teratoma, n=1). Primary tumors were available for evaluation in 21 cases, of which 18 (86%) showed histopathologic evidence of chronic sun damage. Morphologically, the tumors were predominantly epithelioid (n=13), spindle cell (n=8), desmoplastic (n=1) and pleomorphic / sarcomatoid (n=1). Five of the 23 cases had two or more inactivating NF1 mutations. Of the patients with NF1 mutations, 2 (8.7%) displayed BRAF V600E/K , 2 (8.7%) had NRAS Q61L/Q70X and 1 (4.3%) showed KIT D816V mutation. Non-V600 BRAF mutations were identified in 4 NF1 mutated melanomas & included F468S (case 1); D594N (case 2); S114F, D594N and G758E (case 3) and P74S and P75L (case 4). The non-NF1 mutated melanomas displayed BRAF
P29S and KIT L160V mutations in 18 (40%), 10 (22.2%), 2 (4.4%) and 1 (2.2%) cases. Univariate analysis revealed that non-V600 BRAF and RAC1 P29S mutations were more common in the cohort of NF1 mutated melanomas than the control group (p=0.04), while BRAF V600E mutations were less frequent in the NF1 subtype (p=0.01).
Conclusions: Melanomas with truncating NF1 mutations exhibit a wide range of morphologies and evidence of chronic sun damage in majority of the cases. Melanomas with inactivating NF1 mutations are less likely to harbor BRAF V600E/K mutations, while non-V600 BRAF and RAC1
P29S mutations occur at a higher frequency in these tumors when compared to melanomas without NF1 mutations. Design: This retrospective study enrolled 24 patients undergone wide local excision for DFSP from 2004 to 2010. We performed immunohistochemistry for pSTAT3, ERK, pAkt, mTOR, β-catenin and cyclinD1 oncoproteins involved in signal transduction such as JAK/ STAT3, MEK/ERK, Akt/mTOR and Wnt/β-catenin/cyclin D1 pathways. As a control for immunohistochemical evaluation, 92 cases of dermatofibroma tissues were used.
Results: The mean age of DFSP patients was 35 years in mean (range: 19 ~ 64). The ratio of male:female was 3:5. Local recurrence of tumor was occurred in 38% (9/24) of DFSP (recurrence interval: 6.5 months in mean). The tumor size (the largest diameter) was 29 mm in mean. The mitotic figures was 5/ 10 HPF in mean (range: 1 ~25/ 10HPF). Immunohistochemically, mTOR positive and β-catenin cytoplasmic expressions were observed more often in DFSP (mTOR, 33 % of DFSP vs. 9% of dematofibroma; β-catenin, 33% of DFSP vs. none of dermatofibroma; P < 0.05, respectively). Interestingly, β-catenin cytoplasmic expression in DFSP was correlated with tumor local recurrence (P < 0.05). None of DFSP cases showed pSTAT3 positive, and ERK positive was observed in only a DFSP case. In terms of the histologic variant, there were 8 cases of fibrosarcomatous DFSP and 16 conventional DFSP. Fibrosarcomatous DFSP showed frequent mitotic figures than conventional DFSP (mean/10 HPF: 10 mitoses vs. 3; P < 0.05). Two cases of fibrosarcomatous DFSP invaded muscle and bone tissue, which revealed frequent mitotic figures than subcutaneous extension cases (mean/10 HPF: 3 mitoses vs. 10; P < 0.05). Local recurrence occurred more commonly in fibrosarcomatous DFSP than in conventional DFSP (63% of fibrosarcomatous vs. 31% of conventional; P < 0.05). One case of fibrosarcomatous DFSP showed metastasis to pleura at 2 years after excision. CyclinD1 was expressed more predominantly in fibrosarcomatous DFSP than in conventional DFSP (P <0.05). Background: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common types of skin cancer. The morphologic features of BCC and SCC are usually distinct, although it is not uncommon to encounter difficult cases with overlapping features. The correct diagnosis is not only important for prognosis, but also crucial for treatment; this has a significant impact for special sites such as the vulva, where SCC with greater than 1 mm tumour thickness is treated with additional groin lymph node dissection. Filaggrin is an integral skin barrier protein in the epidermis, which is normally concentrated at the junction of stratum granulosum and stratum corneum.Given the localization of this protein in the upper layers of the normal epidermis, we present a pilot study assessing the utility of filaggrin as an immunohistochemical marker in distinguishing BCC and SCC. Furthermore, mutations in filaggrin have been shown to cause thinner skin and increased UV penetration to the basal layer. Therefore, we also investigated the role of filaggrin in the pathogenesis of BCC and SCC by comparing filaggrin expression in tumour tissue and adjacent normal epidermis.
Conclusions:
Design: Tissue microarrays (TMA) were constructed using formalin fixed paraffin embedded tissue of 141 cases of SCC and 66 cases of BCC, each case containing duplicate tumour cores and adjacent normal skin. TMA were stained with anti-filaggrin antibody (FLG01, Abcam) and the staining intensity is stratified manually into negative, weak, moderate and strong . To compare filaggrin expression in tumour and adjacent normal epidermis, digitally scanned sections were analyzed for optical density scores.
Results: Filaggrin is expressed in 65.2% of SCC with various intensity, and 0% of BCC (Table-1) . Also, after excluding cases with missing tissue, the remaining pairs showed loss of filaggrin in 96.1% of SCC and 100% of BCC (Table-2 Conclusions: Our preliminary data suggest filaggrin is a potential immunohistochemical marker for differentiating BCC from SCC. Secondly, the loss of normal filaggrin expression in most of the tumours suggests that filaggrin loss may be a risk factor for skin cancer development. In the future, we plan to expand the sample size for validation of preliminary results and analysis of filaggrin expression in relationship to various clinicopathological parameters. Fudan University Shanghai Cancer Center, extent of TILs infiltration was the percentage of total tumor stromal area occupied by mononuclear inflammatory cells on H&E staining, and we defined the presence of TILs when the extent of TILs reached at least 5%. PD-L1 expression in tumor cells was classified into low and high groups according to the mean H-score. And PD-L1 positivity in TILs was defined as H-score of 5 or more.
PD-L1 Expression in Tumour Infiltrating

Results:
We found that expression of PD-L1 in tumour cells and TILs (Fig. 1) were all present in a tumour-stroma interface pattern, consistent with the predominant pattern of TILs infiltration (Fig. 2) . Furthermore, PD-L1 expression in tumour cells and TILs showed a closely parallel relationship (Spearman'rho=0.381, P=0.001). However, PD-L1 expression neither in tumor cells nor in TILs was significantly correlated with other clinicopathological features (Table 1) . In univariate analysis, the disease-specific survival (DSS) was significantly worse in TILs PD-L1pos group than in TILs PD-L1neg group (median DSS: 40.7 months vs. 78.0 months; P=0.008. Table 2 ). In contrast, there was no significant difference in DSS between tumor cell PD-L1high and tumor cell PD-L1low groups (median DSS: 64.4 months vs. 69.2 months; P=0.378. Table 2 ). In multivariate analysis, PD-L1 expression in TILs was an independent factor for poor prognosis (P=0.032. UT -MD Anderson Cancer Center, Houston, TX Background: Cutaneous metastases have a great impact on detection, management, and prognosis of the primary tumor. We have studied 158 cases of cutaneous metastasis of invasive breast carcinoma in 157 females and 1 male to determine the histologic features and distribution of the metastases.
Design: Cases of metastatic breast carcinoma to the skin diagnosed between 2010-2017 were retrieved from our files. 178 cases in 174 patients were found, of which 23 were consultation cases and the remainder originated at our medical centers. Demographic information, tumor site, morphology, depth of invasion, perineural invasion (PNI), perivascular invasion (PVI), adnexal involvement, and clinical findings were collected. Estrogen (ER), Progesterone (PR) and HER2/neu status of both the primary breast and skin metastasis were also gathered.
Results: The primary lesion in 138 patients was invasive ductal carcinoma (IDC) and in 14 patients invasive lobular carcinoma (ILC). Correlation of the primary tumor with the metastasis showed that metastases occurred predominantly in the ipsilateral side (127 cases). The most common distribution was chest wall (117 cases), back & abdomen (8 cases each), scalp (6 cases), shoulder & axilla (5 cases each), neck (4 cases), arm (3 cases), cheek & forehead (1 case each). The metastases from IDC showed 3 main patterns: an interstitial pattern of growth -92 cases, nodular pattern -29 cases, and an inflammatory carcinoma-like pattern (exclusively intravascular) -11 cases. The metastases from ILC showed mostly an interstitial pattern of growth and in 1 case an intravascular pattern. Pagetoid spread was seen in 16 cases and subcutaneous involvement was noted in 49 cases. LVI and PNI were present in 60 and 35 of the cases, respectively. Correlation of PR, ER and HER2/neu status was done in 75 cases and showed 28 cases with different results.
Conclusions: Metastatic breast carcinoma shows predilection for the ipsilateral chest wall but can involve other locations, including abdomen, axilla, and neck which are consistent with the lymphatic draining sites of the mammary gland. In rare cases, aberrant pathways may result in metastasis to other locations (scalp, forehead, cheek). The original histology at the metastatic site is usually preserved. Metastatic carcinoma with interstitial growth pattern can be confused for metastatic carcinoma from other sites and interstitial dermatitis. Immunohistochemical stains plus careful clinical history helped to establish the correct diagnosis.
Emperipolesis May Be Seen in Cutaneous
Xanthogranulomas: A Multi-Institutional Observation Dartmouth-Hitchcock Med.Ctr., Hanover, NH Background: Cutaneous Rosai-Dorfman Disease (RDD) may be clinically and histologically difficult to distinguish from other nonLangerhans cell histiocytoses, particularly xanthogranuloma (XG). Pathologists use S100 immunopositivity, abundant plasma cells, and the presence of emperipolesis to differentiate RDD histologically. However, S100 expression has been reported in XG and in practice we have observed emperipolesis in cases otherwise clinicopathologically consistent with XG. The purpose of this study was to evaluate and document occasional emperipolesis observed in XG and further characterize subtle histologic findings of XG.
Design: A pathology database search of our institution (between 1/2011 and 12/2016) yielded 35 cases with XG as diagnosis or among a differential diagnosis. Slides and medical records were reviewed, and the histologic features were evaluated. S100, CD68 and CD1a immunohistochemistry were used to further evaluate all lesions exhibiting emperipolesis.
Results: Emperipolesis was identified in 5 of 35 cases. Additionally, 5 histologically similar cases were contributed by colleagues at peer institutions, resulting in 10 total: 7 were clinically and histologically consistent with XG, and 3 raised a histologic differential diagnosis of XG versus RDD while their clinical presentations favored XG. Patient ages ranged from 19 months to 59 years, all had solitary subcentimeter papules, and none had lymphadenopathy or systemic involvement. All biopsies showed emperipolesis of lymphocytes and/or eosinophils in large histiocytes (a prominent feature in 5 cases including those with a differential diagnosis) along with foamy mononuclear forms and Touton giant cells. Notably, none of these cases showed abundant plasma cells, as is common in RDD. Nine cases showed variable S100 expression: focal/weak expression (4 cases), focal/strong (1 case), diffuse/moderate (2 case), and diffuse/strong (2 case). Histiocytes in all cases were CD68 positive and CD1a negative. Background: Despite abundant information on skin malignancies associated with solid organ transplantation (SOT) in adults, limited information exists regarding malignant and nonmalignant skin changes in children. Our aim was to describe skin biopsy changes in pediatric patients with SOT and correlate these changes with clinical and prognostic findings.
Design: Retrospective cohort study of STO recipients under 20 years of age followed at Children's Hospital of Pittsburgh who had an allograft biopsy (heart, lung, kidney, intestine, liver and multivisceral) from July 2015 to July 2017, with at least 3 months of follow-up. The subgroup with skin biopsies was selected and the final diagnoses (dx) and clinical histories reviewed. Statistical analysis was performed using SPSS 22.
Results: There were 433 SOT recipients (164 liver, 135 heart, 78 bowel, 44 kidney, 7 lung and 5 multivisceral), with mean age of 10.8 ± 5.4 years, 237 (54.7%) males and follow-up after transplant (tx) from 3 months to 18 years (mean 5.7 years ± 4.2). 49 skin biopsies were performed in 45 patients (10.3%). Interface and perivascular dermatitis was identified at histology in 22/49 (44.8%) biopsies. After clinicopathological correlation, graft versus host disease (GVHD) was diagnosed in 12 patients; viral infection in 4 (3/4 adenovirus); drug reaction in 2; and 2 cases were non-specific. GVHD was found in 9/78 (11.5%) of bowel and 3/164 (1.8%) of liver tx recipients (p=0.0087). GVHD manifested within 100 days after tx in 9/12 cases (75%); two patients died. Other findings included: skin infections (14 biopsies/12 patients); benign skin tumors (4); scar post-surgical procedure (4); subcutaneous Burkitt lymphoma (2); and anetoderma (1). The etiology of infectious processes was identified in 7/14 (50%) cases: 5/14 (35.7%) were HPV-related, one mycobacterial and one fungal. Intriguingly, 2 liver transplant cases showed neutrophilic dermatitis and/or vasculitis and kidney biopsies with IgA nephropathy confirming HenochSchonlein purpura.
Conclusions: Ten percent of pediatric SOT recipients underwent to skin biopsies. GVHD more frequenty follows bowel tx but also occurs after liver tx. Clinicopathological correlation is indispensable in patients with interface/perivascular dermatitis to identify its etiology. In liver tx recipients a peculiar association with neutrophilic dermatitis and/or vasculitis and IgA nephropathy was found. This should be considered in the diagnostic work up of liver tx patients with leucocytoclasic vasculits. Background: Atypical melanocytic lesions infrequently require additional ancillary testing for enhanced classification via identification of copy number variations (CNV). However, Spitzoid melanocytic lesions comprise a majority of ambiguous lesions tested with ancillary molecular methodologies, such as fluorescence in-situ hybridization (FISH). CDKN2A (9p21.3), a known tumor suppressor in melanoma, is one loci evaluated within the expanded eight probe FISH assay [6p25 (RREB1), 6q23 (MYB), 11q13 (CCND1), 8q24 (MYC) and 9p21.3 (CDKN2A), centromeres 6, 8 and 9] utilized at our institution. Homozygous loss of CDKN2A is a known molecular alteration in melanoma, however isolated heterozygous loss by FISH is not well characterized and seen in 7.7% of our cohort with chromosomal abnormalities. In this study we evaluate heterozygous loss of CDKN2A, an equivocal FISH finding, with comparative methodologies p16 immunohistochemistry (IHC) and SNParray.
Design: Ambiguous melanocytic lesions with isolated heterozygous loss of CDKN2A (monosomy 9) by FISH were identified (N=14). Available tissue was recalled, DNA extracted from formalin fixed paraffin embedded tissue (N=8) for SNParray (Affymetrix, Oncoscan V3), and clinical follow-up obtained. p16 IHC was performed on available cases (N=9). Control tissue from histologically and FISH negative nevi (2) and melanomas (2) were used to verify results.
Results: Fourteen cases (4M;10F; mean age 27 years, range 2-54 years) showed isolated heterozygous loss of CDKN2A by FISH, with no evidence of recurrence after complete excision. Cases had a predominant spitzoid morphology (N=10), dermal mitoses, and an increased Ki-67 index. Of the tested cases (N=8), five cases (cases 1, 4, 6, 7, 8) Vancouver General, University of British Columbia, Vancouver, BC Background: Primary dermal melanoma (PDM) is a rare malignancy which histologically mimics melanoma metastasis, but carries a significantly more favorable prognosis. Diagnosis of PDM cannot be established on histologic grounds alone, but requires absence of evidence of melanoma elsewhere by clinical history and whole-body imaging studies. Despite unique characteristics in biologic behavior of these often deep dermal melanomas, limited data on molecular characterization is available from isolated case reports, in some of which diagnosis of primary dermal melanoma remains doubtful due to adverse outcome. Considering the favorable prognosis associated with PDM and stark contrast in biologic behavior when compared to nodular and metastatic melanoma, we studied a larger case series of PDM to determine mutational frequency in genes with high prevalence of mutations in metastatic melanomas, as well as in non-metastatic dermal melanocytic proliferations such as blue nevi.
Design: Studies were approved by respective Institutional Review Boards. Nine cases fulfilling strict histologic criteria of primary dermal melanoma were identified in patients with absent history of melanoma elsewhere, negative sentinel node biopsies and/or PET scans, as well as uneventful clinical history upon follow-up. DNA was extracted from FFPE-tissue, and eight cases passed quality control measures and were subjected to targeted exon sequencing.
Results: BRAF/NRAS hotspot mutations were detected in four of eight tumors. Two cases showed probable low-activating BRAF or NRAS mutations in combination with additional aberrations in other MAPKpathway effectors, suggesting that a majority of primary dermal melanomas relies on MEK-ERK signaling. No oncogenic mutations were identified in two cases. Furthermore, none of the analyzed tumors showed activating mutations in Gα subunits, including GNAQ and GNA11.
Conclusions: Although primary dermal melanoma is genetically heterogeneous, our findings suggest the predominance of MAPK pathway aberrations, in agreement with the mutational profile of cutaneous melanomas in general. Due to absence of genetic overlap with other distinct primary dermal melanocytic proliferations, in particular blue nevi, mutational profiling of GNAQ/GNA11 will unlikely aid in the difficult differential diagnosis of PDM versus melanoma metastasis. Furthermore, our findings suggest potential benefit of BRAF/MEK inhibition for disease control in rare instances of PDM metastases. Design: Five patients were identified with skin shave biopsies performed between 2011 and 2017. All cases underwent histologic examination and immunohistochemical analysis including p16, HMB-45, and/or Ki-67/MART-1. Three of 5 cases underwent SNP array testing and sequencing analysis for GNAQ and GNA11 mutations and common BRAF mutations.
Results: Patients demonstrated a wide age range from 6 to 67 years, and 4/5 patients were male. The lesions were located on the head/neck (2), back (2) and lower extremity (1). Histology showed a combined melanocytic proliferation which included a conventional nevus with varying atypia and a deeper spindle cell component with primitive nuclei, fascicular-like growth and occasional Verocay body-like structures without maturation with dermal descent. Two cases demonstrated rare mitotic figures and cytologic atypia. Necrosis was not noted. HMB-45 stain showed gradual decrease in dermal expression expected for a nevus in 2 cases, while 3 cases demonstrated patchy dermal staining. Diffuse expression of p16 and ki-67 low-labeling index was seen. No GNAQ, GNA11 or common BRAF mutations were identified in 3 analyzed cases. Two cases showed no chromosomal numerical abnormalities (CNAs); one case showed numerous CNAs involving chromosomes 3, 8, 11 and 15. A diagnosis of atypical combined nevus was rendered in 4 cases with a component resembling a cellular blue nevus mentioned in 3. The lesion with multiple CNAs was diagnosed as borderline. A sentinel lymph node biopsy performed in this case was negative.
Conclusions:
We report a 5-case series of melanocytic tumors with a schwannian morphology resembling peripheral nerve sheath tumors. While some morphologic findings resemble cellular blue nevi, other features including pattern of HMB-45 staining, lack of GNAQ and/or GNA11 mutations and combined junctional and dermal morphology are not typical of this nevus variant. Such lesions may represent a distinct category of nevi or borderline melanocytic tumors. Awareness of this phenotype is important to ensure accurate classification and prevent misdiagnosis. 
CD10 Is Expressed in Endothelial Cells
Kasugai City Hospital
Background: Glomus-cell associated benign lesions (GCABL) have been classified broadly into conventional solid glomus tumor (CSGT) and glomangioma. Recently, glomangioma tends to be considered as a kind of venous malformation and referred to as glomuvenous malformation (GVM). However, except for typical cases, histological differentiation between CSGT and GVM is often arbitrary, and immunohistochemical characteristics of vascular endothelial cells (ECs) of these lesions are not known. The aim of this study is to examine pathological significance of CD10 expression in ECs of GVM, and investigate its pathological attribute on the classification in benign vascular tumor/malformation.
Design: Forty-five cases of GCABL of skin and subcutis were divided histologically into GVM and CSGT, and stained immunohitochemically with antibodies to CD10, CD31, CD34, podoplanin, and GLUT1. As control studies, cavernous hemangiomas (venous malformation) (5 cases), arteriovenous malformation (5 cases), lobular capillary hemangiomas (10 cases), cherry hemangiomas (5 cases), and normal skin/subcutis (10 cases) with various sized vascular vessels were examined as well.
Results: GCABLs were composed of 10 cases of GVM and 35 cases of CSGT. Immunohistochemical expression of CD10 in ECs of each case is summarized in Table 1 . Of note is that CD10 in GVM showed high positivity (50%) in contrast to CSGT (9%). In GVM, 5/10 (50%) were highly positive, 3/10 (30%) mildly positive, and 2/10 (20%) negative. In CSGT, 3/35(9%) were highly positive, 12/35 (34%) mildly positive, and 20/35 (57%) negative. CD34 expression in ECs was varied. Podoplanin, and GLUT1 were negative in all the cases. ECs of all cases of cavernous hemangiomas (venous malformation) and arteriovenous malformation showed CD10 positivity. However, CD10 was completely negative in ECs of lobular capillary hemangiomas, cherry hemangiomas, and normal skin/subcutis. Conclusions: CD10 could be a useful marker for vascular malformation as demonstrated in vascular ECs of cavernous hemangiomas (venous malformation) and arteriovenous malformation. Highly frequent positivity for CD10 in vascular ECs of GVM (glomangioma) might indicate that GVM to be vascular malformation in nature, and the term "GVM" is thought to be appropriate. However, the etiological significance of endothelial CD10 expression in the vascular malformation including GVM, and the biological nature (neoplasm or not) of glomus-cell like cells surrounding vascular vessels remain to be studied in future. Wexner Medical Center at The Ohio State University, Columbus, OH Background: Immune therapy has been a mainstay of treatment for melanoma with IL-2, INF-gamma, and BCG therapy used for high stage disease and immune checkpoint inhibitors for adjuvant therapy. However, immunotherapy has not been well studied in nonmelanoma skin lesions. A major pathway involved in immunotherapy is the CD70-CD27 pathway. Recently it has been shown that CD70 is also expressed both on malignant hematological and solid tumor cells. CD70 expression is associated with poor prognosis and is seen in metastatic disease. In thymic tumors, it differentiates between benign versus malignant. It is thought CD70 itself does not have any downstream impact on tumor cells but rather its expression and interaction with CD27 plays a role in pathogenesis by causing proliferation of nTregs and iTregs that in turn can suppress any adaptive anti-tumor response. Furthermore, expression of CD70 promotes exhaustion of effector T-cell responses through the CTLA-4 pathway and PD-1/PDL-1 pathways. Currently CD70 has not been well studied in both benign and malignant skin lesions. In this study, we explore CD70 expression in variety of skin lesions and explore possible mechanisms of action in CD70+ lesions.
Design: Over 300 deidentified patient lesions contained in tissue microarrays and sections from Biomax, National Cancer Institute, University of Virginia, and Ohio State University were stained with CD70 immunonohistochemical stain (monoclonal, clone TNFSF7) and scored from no expression to increasing intensity using a rating of 0-3. Benign and malignant skin lesions included melanoma, nevi, basal cell carcinoma, squamous cell carcinoma, merkel cell carcinoma, dermatofibromas, and dermatofibrosarcoma protuberans (DFSP). Sections that stained positive for CD70 were further studied looking specifically at T-reg and effector T-cell responses using multiparameter fluorescent microscopy.
Results: CD70 staining was seen on membranes, cytoplasm, or both. Also most cases had focal expression. Squamous cell and nonpigment melanoma lesions had the most expression with at least 50 percent of squamous and 20 percent of melanoma cases expressing CD70. CD70 expression was seen in 10-15 percent of cases for basal and merkel cell carcinoma and DFSP. There was no expression seen in dermatofibromas and congenital nevi.
Conclusions: CD70 expression was seen mainly in squamous cell carcinoma and melanoma and was associated with malignant Background: Transducin-like enhancer of split 1 (TLE1) is a gene involved in cell differentiation and Wnt/β-catenin signaling. TLE1 immunohistochemistry is widely used as a biomarker for synovial sarcoma. Recently, we identified TLE1 expression in a subset of melanomas. TLE1 immunohistochemistry has not been well studied in cutaneous tumors. The aim was to investigate TLE1 expression in sebaceous neoplasms, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
Design: Cases of sebaceous adenoma (n=28), sebaceoma (n=12), sebaceous carcinoma (n=19), BCC (n= 20) and SCC (n=20) diagnosed at a tertiary medical center from 2007-2017 were randomly selected. After review, 5 cases (sebaceous adenoma n=2; sebaceoma n=2; SCC n=1) had insufficient tissue remaining and were excluded from the study. TLE1 immunohistochemistry was performed on the remaining 94 cases and positivity was defined as dark brown nuclear staining and graded as 3+ (strong staining of >50% of cells identified at 4x), 2+ (moderate staining of 10-50% of cells at 4x or >50% of cells staining above background at 10x) and 1+ (weak staining of <50% of cells above background at 10x). No visible staining was scored as 0. Staining for TLE1 was considered positive for 2-3+ and negative for 0-1+.
Results: Nuclear TLE1 expression was identified in 25 of 26 (96%) sebaceous adenomas, 8 of 10 (80%) sebaceomas and 17 of 19 (90%) sebaceous carcinomas (Table 1, Figure 1 ). TLE1 positivity was typically diffuse and strong in the mature sebocytes, in comparison to the basaloid cells which often displayed weaker or patchy staining. TLE1 positivity was also identified in 19 of 20 (95%) BCC and 12 of 19 (63%) SCC cases. All of the neoplasms considered to be negative showed weak (1+) staining and none were completely absent of staining. Univ. of Michigan, Ann Arbor, MI Background: Although histologic interpretation remains the gold standard for the diagnosis of melanoma, molecular methods based on the detection of copy number changes by single nucleotide polymorphism (SNP) microarrays or fluorescence in-situ hybridization (FISH) are increasingly being used in the diagnosis of histologically ambiguous lesions. One of the most significant markers of melanoma is homozygous deletion of the CDKN2A gene, which encodes p16. Detection of this abnormality by FISH is considered to correlate with increased risk for adverse outcome and is often used to favor a diagnosis of melanoma.
Design: From our SNP array database of 263 melanocytic tumors we identified 32 cases with homozygous loss of CDKN2A. FISH with a commercially available 9p21 probe for CDKN2A was performed in 14 cases with available material and compared with the SNP array results. For the remaining 18 cases, the results of FISH testing were predicted based on the location of the 9p21 probe relative to the area of homozygous deletion.
Results: The typical pattern on SNP array consisted of deletion of a large portion of 9p or entire chromosome 9 on one allele combined with a smaller deletion of the other allele overlapping the CDKN2A gene. The average size of the area of homozygous deletion was 2.6 MB (range 0.02-13.75 MB). FISH detected homozygous deletions of 9p21 in only 8/14 cases (57%). The average size of deletion in cases with false negative FISH was smaller than in cases with positive FISH: 0.22 MB (range 0.02-0.6 MB) versus 4.26 MB (range 0.25-13.75 MB) respectively. Failure to detect the homozygous CDKN2A deletion was associated with lack of complete overlap between the FISH probe (designed with a larger overhang towards the p-terminus) and an area of homozygous deletion that was small or extended only towards the centromere (see Figure below for the 6 cases with false negative FISH results). For the 18 cases without FISH, the location of the probe relative to area of deletion predicted detection of homozygous loss in 14 cases (61%).
Conclusions:
We report a relatively high rate of false negative FISH results (41%) for detection of homozygous loss of CDKN2A gene compared to SNP array, especially when the deleted area is small (<0.6 MB) or asymmetrically located. This represents a significant diagnostic pitfall when using FISH in the diagnosis of difficult melanocytic tumors.
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